Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Sacituzumab Govitecan + Pembrolizumab for Triple Negative Breast Cancer
Recruiting1 awardPhase 2
Chapel Hill, North Carolina
This trial is testing whether sacituzumab govitecan or pembrolizumab are safe and effective for treating triple negative breast cancer that has spread to other parts of the body and is PD-L1-negative.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.